Fibroblast growth factor receptor fusion (FGFR fusion)
case report
malignant transformation
spinal cord glioma
Journal
Journal of spine surgery (Hong Kong)
ISSN: 2414-469X
Titre abrégé: J Spine Surg
Pays: China
ID NLM: 101685460
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
15
03
2021
accepted:
20
05
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
5
11
2021
Statut:
ppublish
Résumé
Molecular mechanisms of malignant transformation in spinal cord gliomas are not well-understood. Our objective was to investigate genetic causes of malignant transformation in a primary spinal cord glioma. A 32-year-old female patient presented with bilateral lower extremity weakness and was diagnosed with a primary spinal cord glioma from T9 to T12, with a syrinx extending from the craniocervical junction to the conus. She underwent resection in 2006. Pathology showed an abundance of Rosenthal fibers, calcification and degenerative features consistent with a low-grade pilocytic astrocytoma. She presented in 2020 with tumor recurrence and underwent re-resection. Whole exome sequencing, DNA methylation profiling and immunohistochemistry were performed on her initial and recurrent tumor samples. Immunohistochemical profiling of her recurrent tumor showed pleomorphic cells with extensive necrosis consistent with a high-grade glioma. DNA methylation profiling showed that the initial tumor clustered with pilocytic astrocytomas, whereas the recurrent lesion clustered with anaplastic astrocytomas, confirming malignant transformation. Whole-exome sequencing showed interim acquisition of a rare fibroblast growth factor receptor-transforming acidic coiled-coil (
Identifiants
pubmed: 34734147
doi: 10.21037/jss-21-24
pii: jss-07-03-434
pmc: PMC8511564
doi:
Types de publication
Case Reports
Langues
eng
Pagination
434-438Informations de copyright
2021 Journal of Spine Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jss-21-24). The authors have no conflicts of interest to declare.
Références
Science. 2012 Sep 7;337(6099):1231-5
pubmed: 22837387
Neurosurg Focus. 2015 Aug;39(2):E14
pubmed: 26235012
Curr Neurol Neurosci Rep. 2011 Jun;11(3):320-8
pubmed: 21327734
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):965-971
pubmed: 29485076
Neuro Oncol. 2017 Apr 1;19(4):475-483
pubmed: 27852792
Acta Neuropathol Commun. 2020 Jul 8;8(1):101
pubmed: 32641156
J Neuropathol Exp Neurol. 2021 Feb 22;80(3):283-285
pubmed: 33212490
Lancet Oncol. 2008 Jun;9(6):600
pubmed: 18510992
Neuro Oncol. 2021 Jul 1;23(7):1148-1162
pubmed: 33346834
Curr Treat Options Neurol. 2003 May;5(3):207-212
pubmed: 12670409